A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash
To the Editor: An acneiform rash develops on the face and trunk in up to 90% of patients receiving cetuximab. The impact this rash has on the quality of life (QoL) and psychosocial well-being can be severe, and its development might lead to reduced cetuximab dosing and adverse clinical outcomes. 1 Current interventions include topical steroids or oral antibiotics (sometimes as part of a multi-drug regimen), which might be associated with adverse events (AEs), microbial resistance, and polypharmacy. To date, no topical agent in a prospective, randomized study has shown the benefit of preventing epidermal growth factor receptor inhibitor (EGFRI)einduced acneiform rash.
Dapsone exerts its anti-inflammatory effects via suppression of neutrophil recruitment; inhibition of the release of prostaglandins, leukotrienes, and lipopolysaccharide-stimulated interleukin 8 production in human keratinocytes 2, 3 ; and a decrease of mononuclear cell tumor necrosis factor-production. 4, 5 It also blocks the generation of toxic, oxygen-derived radicals, thereby protecting 
Fig 1.
Lesion count differences between control-treated and dapsone-treated sides. Presented are the individual participant trajectories for lesion count differences between control-treated and dapsone-treated sides of the face and chest for those participants who completed the day 28 6 2 evaluation. Values [0 indicate higher lesion counts on the control-treated side than on the dapsonetreated side of the body. Also included is a fitted trajectory to depict the overall trend in the difference in lesion counts for the group as a whole.
against neutrophil-and eosinophil-mediated injury.
Adult patients with metastatic colorectal cancer or head and neck squamous cell carcinoma receiving cetuximab were randomized to apply 1 mL of topical dapsone 5% gel (50 mg dapsone/g) to either the right or left side of the face and chest twice daily and a moisturizer (Vanicream Lite Lotion) to the contralateral side (control). All patients received oral minocycline 100 mg once daily. Study visits occurred on day 0 (the trial start), day 14 (a visit in which lesion counts [LC] and standardized photography [SP] were done), day 28 (the last visit of the trial; LC and SP were also done), and day 42 (the safety visit). The dermatologic QoL was measured using the Skindex-16 and the functional assessment of cancer therapy epidermal growth factor receptor inhibitor (FACT-EGFRI) 18 questionnaires for each side of the face and chest on day 14 6 2 and day 28 6 2. The primary and secondary endpoints were a 20% reduction in papulopustular LCs on the dapsone-treated side compared with the moisturizer-treated side on day 28 and day 14, respectively.
Eleven patients (9 men, 2 women; age range, 38-66 years) consented and were randomized in this institutional review boardeapproved study. Overall, 8/11 completed the primary outcome evaluation time point. At day 28, the average decrease in lesion counts between the dapsone-and moisturizertreated sides of the face was 30.5%; a 36.7% reduction in lesion counts was observed on day 14 (Table I; Fig 1) . Nine of 11 (82%) participants completed both questionnaires at baseline, 6 of 9 (66.7%) completed at day 14, and 4 of 8 (50%) completed at day 28 (Table II) . Application-site AEs were mild and included xerosis (n ¼ 5); burning (n ¼ 2); skin tightness, pain, or oiliness (n ¼ 1 each); and lacerations (n ¼ 1, unrelated). Other AEs included a metallic taste, dry palms, and fingertip fissures (n ¼ 1 each).
Our study represents an attempt to bridge an important gap in the prophylactic management of cetuximab-induced acneiform rash, by using a nonsteroidal topical agent with anti-inflammatory and antimicrobial properties. An overall but not statistically significant reduction in LCs was observed on the dapsone-treated sides, which is consistent with previous studies using oral antibiotics. Although enrollment ended prematurely limiting the power of the study to observe a statistically significant difference, our findings suggest that topical dapsone 5% gel might represent an alternative in the prophylaxis of cetuximab-induced acneiform rash, but the benefit must be validated in larger studies. 
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Correlation between HPV status via in situ hybridization testing on genital squamous papillomas and risk for cervical dysplasia or other anogenital HPV-related complications: A case-control study
To the Editor: Human papillomavirus (HPV) is a cause of cervical cancer and condylomata acuminata. [1] [2] [3] Though condylomata are often recognized clinically, specimens submitted for histopathologic interpretation can be tested for HPV serotypes via in situ hybridization (ISH). 4 Our study evaluated the relationship between tissue HPV expression in genital squamous papillomas and cervical or other anogenital HPV-related complications.
We retrospectively reviewed all skin biopsies of genital squamous papillomas that were serotyped for low-and high-risk HPV strains by ISH in women from 2004 through 2014 at our institution. Results were tabulated based on HPV serotype, Papanicolaou smear abnormalities (including atypical cells of undetermined significance, low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion, cervical intraepithelial neoplasia I-III) and other HPV-related diagnoses (eg, anal intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia). Statistical analysis included 2-tailed Fisher's exact test, t test, Chi square, and Anova analysis, and a P value of #.05 was considered statistically significant.
We included 147 specimens from 243 patients. Table I (Table II) . No specimen was positive for both low-and highrisk HPV. No difference in Papanicolaou smear abnormalities was found when comparing patients whose specimens tested positive for any type of HPV with those whose specimens tested negative (35% vs 34%, P ¼ .94) or when comparing patients whose specimens tested positive for low-risk HPV with those that tested positive for high-risk HPV (38% vs 14%, P ¼ .19). Lower rates of other anogenital HPVrelated complications were found in patients with HPV-positive compared with patients with HPVnegative skin specimens (7% vs 17%, P ¼ .08). Further subgroup testing revealed no differences in anogenital HPV-related complications in highversus low-risk HPV types (14% vs 6%, respectively; P ¼ .39). One patient was found to have evidence of urothelial carcinoma in situ (n ¼ 1) on vaginal Papanicolaou smear and had an HPV-negative condyloma.
The average time between abnormal Papanicolaou smear and HPV ISH testing of skin biopsies did not differ between those testing positive and negative for any HPV serotype (Table II) . In the group that had negative results for HPV ISH testing of skin specimen, 17% had abnormal Papanicolaou smears found after the skin biopsy was obtained. For those with positive HPV ISH test 
